CG Invites

We strive to be a global biopharma leader whose mission is

to develop innovative, life-changing medicine


Polmacoxib + Pregabalin

  • Indication
    Neuropathic pain (e.g., diabetic neuropathy, fibromyalgia, postherpetic neuralgia)
  • Development stage
    Phase 1 clinical study completed
  • Mechanism of action and features
    • Combination of polmacoxib and pregabalin for neuropathic pain
    • Anti-inflammatory and analgesic effects are expected to be consistent and strong against neuropathic pain diseases
    • Polmacoxib has a long half-life that increases its persistence compared to conventional anti-inflammatory analgesics.
    • Pregabalin is a neuropathic pain reliever
    • Safety verification through Phase 1 clinical study for healthy individuals

Polmacoxib + Pregabalin